Archive: Company News
Company News: Curetis Reports Financial Results for the First Six Months of 2019
– Strategic transaction to combine businesses with OpGen Inc.
– Revenues increased by approximately 35% year-on-year
– Progressing regulatory product approvals in the U.S. and China
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today reported its financial results for the first six months ended June 30, 2019, and provided a business update for 2019 year-to-date and its outlook for the future. Read more…
Company News: Curetis Group Subsidiary Ares Genetics Signs R&D and Option Agreement with Leading Global IVD Corporation
— R&D collaboration to develop NGS-based predictive antibiotic resistance testing powered by ARESdb
— Partner to fund R&D and obtains option to license ARESdb and ARES Technology Platform for human clinical diagnostic use
Elements of this announcement contain or may contain inside information within the meaning of Article 7(1) of the Market Abuse Regulation.
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that its wholly-owned subsidiary Ares Genetics GmbH (“Ares Genetics”), Vienna, Austria, has entered into a multi-phase partnership with an undisclosed leading global in vitro diagnostics corporation (the “Partner”) to jointly develop diagnostic solutions for infectious disease testing based on next-generation sequencing (“NGS”) technology. Read more…
Company News: Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses
— Combined company creates a commercial-stage, transatlantic diagnostics company focusing on data-driven solutions for molecular microbiology
— Combined company to be headquartered in Gaithersburg, MD, USA
— Transaction is supported by the boards of OpGen and Curetis
— Transaction subject to approval by both companies’ shareholders and debt financing providers
— Conference call scheduled for September 4, 2019, at 9:00 am Eastern / 3:00 pm Central European Time Read more…
Company News: ISA Pharmaceuticals Strengthens its Supervisory Board with the Addition of Dr. Markwin Velders
– Seasoned biotech expert to support corporate development
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the addition of Dr. Markwin Velders to its Supervisory Board. Dr. Velders brings many years of experience in the biotech industry and currently holds a position as VP Operations and Managing Director at Kite Pharma EU, a leading company in the field of immuno-oncology and cell therapy. Read more…